Cardiac-targeted rAAV5-S100A1 gene therapy protects against adverse remodeling and contractile dysfunction in post-ischemic hearts https://www.biorxiv.org/content/10.1101/2023.03.03.529004v1?med=mas
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.